دورية أكاديمية
Stereotactic body radiation therapy (SBRT) in patients with hepatocellular carcinoma and oligometastatic liver disease
العنوان: | Stereotactic body radiation therapy (SBRT) in patients with hepatocellular carcinoma and oligometastatic liver disease |
---|---|
المؤلفون: | Sabine Gerum, Christian Heinz, Claus Belka, Franziska Walter, Philipp Paprottka, Enrico N. De Toni, Falk Roeder |
المصدر: | Radiation Oncology, Vol 13, Iss 1, Pp 1-9 (2018) |
بيانات النشر: | BMC, 2018. |
سنة النشر: | 2018 |
المجموعة: | LCC:Medical physics. Medical radiology. Nuclear medicine LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
مصطلحات موضوعية: | Liver, HCC, Oligometastatic, SBRT, Medical physics. Medical radiology. Nuclear medicine, R895-920, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
الوصف: | Abstract Background To report our experience with SBRT in primary and secondary liver tumors. Methods We retrospectively analysed 55 patients (70 lesions) with a median follow-up of 10 months (range 1–57) treated from 2011 to 2016. All patients had not been eligible for other local treatment options. Median age was 64 years and 64% were male. 27 patients (36 lesions) suffered from hepatocellular carcinoma (HCC, Child A:78%, Child B:18%, Child C:4%), 28 patients (34 lesions) had oligometastatic liver disease (MD). Treatment planning was based on 4D-CT usually after placement of fiducials. Dose and fractionation varied depending on localization and size, most commonly 3 × 12.5 Gy (prescribed to the surrounding 65%-isodose) in 56% and 5x8Gy (80% isodose) in 20% of the treated lesions. Results Local recurrence was observed in 7 patients (13%) and 8 lesions (11%), resulting in estimated 1- and 2-year local control rates (LC) of 91 and 74%. Estimated 1- and 2-year rates of Freedom from hepatic failure (FFHF) were 42 and 28%. Number of lesions was predictive for LC and FFHF in the entire cohort. Estimated 1- and 2-year overall survival (OS) was 76 and 57%. OS was significantly affected by number of treated lesions and performance status. In the HCC subgroup, pretreatment liver function and gender were also predictive for OS. Maximum acute non-hepatic toxicity was grade 1 in 16% and grade 2 in 10% of the patients. Three HCC patients (11%) developed marked deterioration of liver function (grade 3/4). Conclusions SBRT resulted in high local control and acceptable survival rates in patients with HCC or MD not amendable to other locally-ablative treatment options with limited toxicity. Care should be taken in HCC patients with Child B cirrhosis. |
نوع الوثيقة: | article |
وصف الملف: | electronic resource |
اللغة: | English |
تدمد: | 1748-717X |
Relation: | http://link.springer.com/article/10.1186/s13014-018-1048-4; https://doaj.org/toc/1748-717X |
DOI: | 10.1186/s13014-018-1048-4 |
URL الوصول: | https://doaj.org/article/875a37abca3847b2a5cb0a3bdbce3953 |
رقم الأكسشن: | edsdoj.875a37abca3847b2a5cb0a3bdbce3953 |
قاعدة البيانات: | Directory of Open Access Journals |
تدمد: | 1748717X |
---|---|
DOI: | 10.1186/s13014-018-1048-4 |